title: Anti-TNF therapy: where have we got to in 2005?
abstract: The blockade of TNF has had significant impact on the therapy of a number of chronic autoimmune diseases. In this chapter we review the concepts leading up to this therapy in rheumatoid arthritis (RA), how it spreads into other autoimmune diseases, and how greater understanding of its use has led to augmented therapeutic benefit. There are still many limitations, but the prospects for the future are intriguing.
authors.affiliation: Kennedy Institute of Rheumatology Division, Faculty of Medicine, Imperial College, 1 Aspenlea Road, London W6 8LH, UK. m.feldmann@imperial.ac.uk
authors.forename: Marc
authors.initials: M
authors.lastname: Feldmann
authors.forename: Fionula M
authors.initials: FM
authors.lastname: Brennan
authors.forename: Brian M J
authors.initials: BM
authors.lastname: Foxwell
authors.forename: Peter C
authors.initials: PC
authors.lastname: Taylor
authors.forename: Richard O
authors.initials: RO
authors.lastname: Williams
authors.forename: R N
authors.initials: RN
authors.lastname: Maini
mesh_terms: D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001327:Autoimmune Diseases / Q000188:drug therapy; D016207:Cytokines / Q000037:antagonists & inhibitors; D006801:Humans; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D016207:Cytokines; D014409:Tumor Necrosis Factor-alpha